Business Description
HealthEquity Inc
NAICS : 519290
SIC : 8099
ISIN : US42226A1079
Total Employee Number:
2,814Compare
Compare
Traded in other countries / regions
HQY.USA2HE.GermanyHQY.Mexico Index Membership
Russell 2000Russell 3000 IPO Date
2014-07-31Description
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.27 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.48 | |||||
Debt-to-EBITDA | 1.94 | |||||
Interest Coverage | 6.33 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 4.34 | |||||
Beneish M-Score | -2.81 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.7 | |||||
3-Year EBITDA Growth Rate | 40.2 | |||||
3-Year EPS without NRI Growth Rate | 43.3 | |||||
3-Year FCF Growth Rate | 132.2 | |||||
3-Year Book Growth Rate | 3.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 15.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.45 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.21 | |||||
9-Day RSI | 41.72 | |||||
14-Day RSI | 46.28 | |||||
3-1 Month Momentum % | 7.32 | |||||
6-1 Month Momentum % | -4.69 | |||||
12-1 Month Momentum % | -15.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.44 | |||||
Quick Ratio | 3.44 | |||||
Cash Ratio | 1.95 | |||||
Days Sales Outstanding | 31.9 | |||||
Days Payable | 12.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 6.66 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.68 | |||||
Operating Margin % | 25.96 | |||||
Net Margin % | 17.25 | |||||
EBITDA Margin % | 37.98 | |||||
FCF Margin % | 32.98 | |||||
OCF Margin % | 36.63 | |||||
ROE % | 10.92 | |||||
ROA % | 6.82 | |||||
ROIC % | 8.92 | |||||
3-Year ROIIC % | 116.81 | |||||
ROC (Joel Greenblatt) % | 311.65 | |||||
ROCE % | 10.87 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 31.84 | |||||
Forward PE Ratio | 18.01 | |||||
PE Ratio without NRI | 19.86 | |||||
Shiller PE Ratio | 103.66 | |||||
Price-to-Owner-Earnings | 29.8 | |||||
PEG Ratio | 0.7 | |||||
PS Ratio | 5.56 | |||||
PB Ratio | 3.48 | |||||
Price-to-Free-Cash-Flow | 16.68 | |||||
Price-to-Operating-Cash-Flow | 15.01 | |||||
EV-to-EBIT | 22.12 | |||||
EV-to-Forward-EBIT | 21.56 | |||||
EV-to-EBITDA | 15.41 | |||||
EV-to-Forward-EBITDA | 35.87 | |||||
EV-to-Revenue | 5.85 | |||||
EV-to-Forward-Revenue | 5.52 | |||||
EV-to-FCF | 17.75 | |||||
Price-to-GF-Value | 0.83 | |||||
Price-to-Projected-FCF | 2.29 | |||||
Price-to-DCF (Earnings Based) | 0.64 | |||||
Price-to-DCF (FCF Based) | 0.53 | |||||
Price-to-Median-PS-Value | 0.75 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.79 | |||||
Earnings Yield (Greenblatt) % | 4.52 | |||||
FCF Yield % | 6.21 | |||||
Forward Rate of Return (Yacktman) % | 21.44 |
HealthEquity Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HealthEquity Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2026-12-03 16:30 | In 162 days | ||
| Third quarter earnings results for 2027 | 2026-12-03 | In 161 days | ||
| Second quarter earnings conference call for 2027 | 2026-09-02 16:30 | In 70 days | ||
| Second quarter earnings results for 2027 | 2026-09-02 | In 69 days | ||
| General meeting for 2026 | 2026-06-25 10:00 | In 1 day | ||
| RBC Global Financial Technology Conference | 2026-06-09 13:10 | 87.84 (-0.95%) | ||
| First quarter earnings conference call for 2027 | 2026-05-28 16:30 | 86.56 (-0.73%) | ||
| First quarter earnings results for 2027 | 2026-05-28 | 86.56 (-0.73%) | ||
| JP Morgan Global Technology Conference | 2026-05-19 13:55 | 83.04 (+0.52%) | ||
| Guidance call for 2026 | 2026-05-12 15:00 | 81.65 (-3.33%) |
Show
Entries
Guru Commentaries on NAS:HQY
No articles.
Press Release
Articles on HealthEquity Inc
No articles.
Headlines
See More- 1
May 29, 2026
HealthEquity outlines fiscal 2027 revenue of $1.41B-$1.42B while expanding share repurchase authorization by $1B
Seeking Alpha • 11:25pm
May 28, 2026
HealthEquity Non-GAAP EPS of $1.24 beats by $0.12, revenue of $354.6M beats by $2.3M
Seeking Alpha • 3:17pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers